CoChat

Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

Open access
von Herrath, Matthias, Bain, Stephen C, Bode, Bruce, Clausen, Jesper Ole, Coppieters, Ken, Gaysina, Leylya, Gumprecht, Janusz, Hansen, Troels Krarup, Mathieu, Chantal, Morales, Cristobal, Mosenzon, Ofri, Segel, Stine, Tsoukas, George, Pieber, Thomas R, Ludvik, Bernhard, Prager, Rudolf, Paulweber, Bernhard, Ebenbichler, Christoph F, Keymeulen, B, De Block, C, Grossman, Loren, Houlden, Robyn, Perron, Patrice, Ransom, Thomas, Senior, Peter, Weisnagel, S. John, Woo, Vincent, Dumas, Richard, Thompson, David, Vilsbøll, Tina, Gram, Jeppe, Juhl, Claus Bogh, Hukkanen, Janne, Lahtela, Jorma, Niskanen, Leo, O'Shea, Donal, O'Brien, Timothy, Sreenan, Seamus, Wainstein, Julio, Phillip, Moshe, Knobler, Hilla, Dotta, Francesco, Piatti, Pier Marco, Roberto, Trevisan, Gnasso, Agostino, Gulseth, Hanne, Cooper, John, Pankowska, Ewa, Lukaszewicz, Monika, Wolnik, Bogumił, Manita, Isabel, Marques, Olinda, Roque, Cristina, Príncipe, Rosa Maria, Neves, Celestino, Heitor, Susana, Ruyatkina, L, Dvoryashina, Irina, Vagapova, Gulnar, Belousova, Lidiya, Sergeeva-Kondrachenko, Marina, Peskov, Andrey, Frolova, Elena, Golovach, Albina, Kunitsyna, Marina, Krasnopeeva (Kabachkova), Natalia, Ipatko, Irina, De la Cuesta, Carmen, Tinahones, Francisco José, Rigla, Mercedes, Merino, Juan Francisco, Gómez, Luis Alberto, Fernández, Mercè, Simó, Rafael, Rydén, Mikael, Jendle, Johan, Filipsson, Karin, Eliasson, Björn, Mankovsky, Borys, Lymar, Iurii, Sokolova, Liubov, Myshanych, Galyna, Zlova, Tetiana, Vlasenko, Maryna, Kuskalo -, Petro, Courtney, Hamish, Dayan, Colin, English, Patrick, Heller, Simon, Johnson, Andrew B, Nair, Sunil, Leslie, R. D, Narendran, P, Oliver, Nick, Ramtoola, Shenaz, Shaw, Jim, Viljoen -, Adie, Al-Karadsheh, Amer, Dostou, Jean Marie, Gangi, Sumana, Gottlieb, Peter, Jerkins, Terri, Magnotti, Michael, Marks, Jennifer, Nakhle, Samer, Bonabi, Gholamreza, Myers, Lyle, Pratley, Richard, Hagopian, William, Pettus, Jeremy, von Scholten, Bernt Johan, Wesley, Johnna D, Kreiner, Frederik F · 2021 · The Lancet Diabetes & Endocrinology

The DOI matches its Crossref record; 35 of the 36 references it cites were found in a registry or an index.

Abstract

Background Type 1 diabetes is characterised by progressive loss of functional β-cell mass, necessitating insulin treatment. We aimed to investigate the hypothesis that combining anti-interleukin (IL)-21 antibody (for low-grade and transient immunomodulation) with liraglutide (to improve β-cell function) could enable β-cell survival with a reduced risk of complications compared with traditional immunomodulation.Methods This randomised, parallel-group, placebo-controlled, double-dummy, double-blind, phase 2 trial was done at 94 sites (university hospitals and medical centres) in 17 countries. Eligible participants were adults aged 18-45 years with recently diagnosed type 1 diabetes and residual β-cell function. Individuals with unstable type 1 diabetes (defined by an episode of severe diabetic ketoacidosis within 2 weeks of enrolment) or active or latent chronic infections were excluded. Participants were randomly assigned (1:1:1:1), with stratification by baseline stimulated peak C-peptide concentration (mixed-meal tolerance test [MMTT]), to the combination of anti-IL-21 and liraglutide, anti-IL-21 alone, liraglutide alone, or placebo, all as an adjunct to insulin. Investigators, participants, and funder personnel were masked throughout the treatment period. The primary outcome was the change in MMTT-stimulated C-peptide concentration at week 54 (end of treatment) relative to baseline, measured via the area under the concentration-time curve (AUC) over a 4 h period for the full analysis set (intention-to-treat population consisting of all participants who were randomly assigned). After treatment cessation, participants were followed up for an additional 26-week off-treatment observation period. This trial is registered with ClinicalTrials.gov, NCT02443155.Findings Between Nov 10, 2015, and Feb 27, 2019, 553 adults were assessed for eligibility, of whom 308 were randomly assigned to receive either anti-IL-21 plus liraglutide, anti-IL-21, liraglutide, or placebo (77 assigned to each group). Compared with placebo (ratio to baseline 0·61, 39% decrease), the decrease in MMTT-stimulated C-peptide concentration from baseline to week 54 was significantly smaller with combination treatment (0·90, 10% decrease; estimated treatment ratio 1·48, 95% CI 1·16-1·89; p=0·0017), but not with anti-IL-21 alone (1·23, 0·97-1·57; p=0·093) or liraglutide alone (1·12, 0·87-1·42; p=0·38). Despite greater insulin use in the placebo group, the decrease in HbA 1c (a key secondary outcome) at week 54 was greater with all active treatments (-0·50 percentage points) than with placebo (-0·10 percentage points), although the differences versus placebo were not significant. The effects diminished upon treatment cessation. Changes in immune cell subsets across groups were transient and mild (<10% change over time). The most frequently reported adverse events included gastrointestinal disorders, in keeping with the known side-effect profile of liraglutide. The rate of hypoglycaemic events did not differ significantly between active treatment groups and placebo, with an exception of a lower rate in the liraglutide group than in the placebo group during the treatment period. No events of diabetic ketoacidosis were observed. One participant died while on liraglutide (considered unlikely to be related to trial treatment) in connection with three reported adverse events (hypoglycaemic coma, pneumonia, and brain oedema).Interpretation The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile. Efficacy and safety should be further evaluated in a phase 3 trial programme.Funding Novo Nordisk.

Overview

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(21)00019-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 35 references

Cited by

See all 199

Metadata

Authors
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., Mosenzon, O., Segel, S., Tsoukas, G., Pieber, T. R., Ludvik, B., Prager, R., Paulweber, B., Ebenbichler, C. F., Keymeulen, B., De Block, C., Grossman, L., Houlden, R., Perron, P., Ransom, T., Senior, P., Weisnagel, S. J., Woo, V., Dumas, R., Thompson, D., Vilsbøll, T., Gram, J., Juhl, C. B., Hukkanen, J., Lahtela, J., Niskanen, L., O'Shea, D., O'Brien, T., Sreenan, S., Wainstein, J., Phillip, M., Knobler, H., Dotta, F., Piatti, P. M., Roberto, T., Gnasso, A., Gulseth, H., Cooper, J., Pankowska, E., Lukaszewicz, M., Wolnik, B., Manita, I., Marques, O., Roque, C., Príncipe, R. M., Neves, C., Heitor, S., Ruyatkina, L., Dvoryashina, I., Vagapova, G., Belousova, L., Sergeeva-Kondrachenko, M., Peskov, A., Frolova, E., Golovach, A., Kunitsyna, M., Krasnopeeva (Kabachkova), N., Ipatko, I., De la Cuesta, C., Tinahones, F. J., Rigla, M., Merino, J. F., Gómez, L. A., Fernández, M., Simó, R., Rydén, M., Jendle, J., Filipsson, K., Eliasson, B., Mankovsky, B., Lymar, I., Sokolova, L., Myshanych, G., Zlova, T., Vlasenko, M., Kuskalo -, P., Courtney, H., Dayan, C., English, P., Heller, S., Johnson, A. B., Nair, S., Leslie, R. D., Narendran, P., Oliver, N., Ramtoola, S., Shaw, J., Viljoen -, A., Al-Karadsheh, A., Dostou, J. M., Gangi, S., Gottlieb, P., Jerkins, T., Magnotti, M., Marks, J., Nakhle, S., Bonabi, G., Myers, L., Pratley, R., Hagopian, W., Pettus, J., von Scholten, B. J., Wesley, J. D., & Kreiner, F. F.
Affiliations
  • Swansea University (GB)
  • Emory University (US)
  • Novo Nordisk (Denmark) (DK)
  • Kazan Federal University (RU)
  • Medical University of Silesia (PL)
  • Aarhus University Hospital (DK)
  • Universitair Ziekenhuis Leuven (BE)
  • Hebrew University of Jerusalem (IL)
  • McGill University (CA)
  • Medical University of Graz (AT)
Corresponding author
Pieber, Thomas R
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2021-04
Volume
9
Issue
4
Pages
212-224
ISSN
2213-8587 (ISSN-L)
OpenAlex
W3134851073
Cited by
186
References
36
Citations by year
2026: 31 · 2025: 40 · 2024: 32 · 2023: 33 · 2022: 29 · 2021: 21
FWCI
16.27
Type
journal article
Language
en
Open access
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Cronfa (Swansea University) (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Use Siena air (University of Siena) (submittedVersion)
  • VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Funders
Novo Nordisk
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
type 1 diabetes, liraglutide, beta-cell preservation, immunomodulation, C-peptide, mixed meal tolerance test, residual beta-cell function, recent-onset type 1 diabetes, adults, GLP-1 receptor agonists, beta-cell survival, safety and tolerability
MeSH terms
Liraglutide, Interleukin-21, Adult, Antibodies, Monoclonal, B-Lymphocytes, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Interleukins, Male, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-8587(21)00019-x
The paper
von Herrath, M., Bain, S. C., Bode, B., Clausen, J. O., Coppieters, K., Gaysina, L., Gumprecht, J., Hansen, T. K., Mathieu, C., Morales, C., Mosenzon, O., Segel, S., Tsoukas, G., Pieber, T. R., Ludvik, B., Prager, R., Paulweber, B., Ebenbichler, C. F., Keymeulen, B., . . . Kreiner, F. F. (2021). Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(21)00019-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.